Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells.

Insulin-like growth factor receptor 1 (IGFR1) plays a crucial role in oncogenic transformation [C. Sell et al., Mol. Cell. Biol., 14: 3604-3612,1994]. Compared with the normal human mammary epithelial cell line MCF12A, MCF7 human mammary carcinoma cells overexpress IGFR1 on the cell surface. To measure the effects of IGFR1 inhibition on tumor cells, we tested two mouse neutralizing antibodies against human IGFR1 in cell-based assays. Both MAB391 and anti-IR3 antibodies inhibit IGFR1 autophosphorylation upon IGF-I ligand stimulation with IC50s of 0.58 and 0.80 nM, respectively. When cells were treated with neutralizing anti-IGFR1 antibodies for > or = 4 h, the total receptor level was dramatically decreased. IGF-I-stimulated activation of AKT was also inhibited by anti-IGFR1 antibodies. Furthermore, MAB391 and anti-IR3 inhibited the growth of MCF7 cells in soft agar. In addition to MCF7 cells, MAB391 also inhibited IGFR1 autophosphorylation and induced IGFR1 down-modulation in HT29 colorectal and Du145 prostate cancer cells. Therefore, neutralizing antibodies against IGFR1 represent a valid approach to inhibit growth of tumor cells.

[1]  G. Sharma,et al.  Ligand-regulated Internalization, Trafficking, and Down-regulation of Guanylyl Cyclase/Atrial Natriuretic Peptide Receptor-A in Human Embryonic Kidney 293 Cells* , 2002, The Journal of Biological Chemistry.

[2]  R. Rotem-Yehudar,et al.  Association of Insulin-like Growth Factor 1 Receptor with EHD1 and SNAP29* , 2001, The Journal of Biological Chemistry.

[3]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[4]  Y. Wu,et al.  Plasma Insulin-Like Growth Factor-I and Serum IGF-Binding Protein 3 Can Be Associated with the Progression of Breast Cancer, and Predict the Risk of Recurrence and the Probability of Survival in African-American and Hispanic Women , 1999, Oncology.

[5]  Julian Downward,et al.  Akt/PKB localisation and 3′ phosphoinositide generation at sites of epithelial cell–matrix and cell–cell interaction , 1999, Current Biology.

[6]  L. Whitesell,et al.  Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. , 1998, Cancer research.

[7]  K. Reiss,et al.  Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  D. Leroith,et al.  Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. , 1998, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[9]  M. Mandalà,et al.  Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer. , 1998, European journal of endocrinology.

[10]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[11]  N. Webster,et al.  Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. , 1998, Cancer research.

[12]  G. Condorelli,et al.  Insulin-like Growth Factor-I Receptor Internalization Regulates Signaling via the Shc/Mitogen-activated Protein Kinase Pathway, but Not the Insulin Receptor Substrate-1 Pathway* , 1998, The Journal of Biological Chemistry.

[13]  L. Sepp-Lorenzino.  Structure and function of the insulin-like growth factor I receptor , 1998, Breast Cancer Research and Treatment.

[14]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[15]  A. Ferber,et al.  A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. , 1996, Cancer research.

[16]  A. D'ercole.  Insulin-like growth factors and their receptors in growth. , 1996, Endocrinology and metabolism clinics of North America.

[17]  J. Ilan,et al.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Roberts,et al.  Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. , 1995, Endocrinology.

[19]  J. Mendelsohn,et al.  Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. , 1994, The Journal of biological chemistry.

[20]  D. Coppola,et al.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.

[21]  S. Asa,et al.  Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Ullrich,et al.  Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.

[23]  T. Gansler,et al.  Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. , 1989, The American journal of pathology.

[24]  C. Osborne,et al.  Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. , 1989, Cancer research.

[25]  C. Osborne,et al.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.

[26]  E. Rutanen,et al.  Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. , 1988, Cancer research.

[27]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[28]  Stampfer,et al.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. , 1999, Journal of the National Cancer Institute.